Literature DB >> 19132749

Bayesian models identify specific lymphoproliferative disorders associated with hepatitis C virus infection.

Luca Arcaini, Cristiana Pascutto, Francesco Passamonti, Raffaele Bruno, Michele Merli, Silvia Rizzi, Ester Orlandi, Cesare Astori, Sara Rattotti, Marco Paulli, Mario Lazzarino.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19132749     DOI： 10.1002/ijc.24162

Source DB:  PubMed          Journal:  Int J Cancer        ISSN： 0020-7136            Impact factor:   7.396


× No keyword cloud information.
  4 in total

1.  Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas.

Authors:  Michele Merli; Marco Frigeni; Laurent Alric; Carlo Visco; Caroline Besson; Lara Mannelli; Alice Di Rocco; Angela Ferrari; Lucia Farina; Mario Pirisi; Francesco Piazza; Véronique Loustaud-Ratti; Annalisa Arcari; Dario Marino; Antonello Sica; Maria Goldaniga; Chiara Rusconi; Massimo Gentile; Emanuele Cencini; Francesco Benanti; Maria Grazia Rumi; Virginia Valeria Ferretti; Paolo Grossi; Manuel Gotti; Roberta Sciarra; Maria Chiara Tisi; Isabel Cano; Valentina Zuccaro; Francesco Passamonti; Luca Arcaini
Journal:  Oncologist       Date:  2018-12-14

2.  Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients.

Authors:  Elisa Rumi; Francesco Passamonti; Chiara Elena; Daniela Pietra; Luca Arcaini; Cesare Astori; Silvia Zibellini; Emanuela Boveri; Cristiana Pascutto; Mario Lazzarino
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

Review 3.  Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy.

Authors:  Luca Arcaini; Michele Merli; Stefano Volpetti; Sara Rattotti; Manuel Gotti; Francesco Zaja
Journal:  Clin Dev Immunol       Date:  2012-08-26

Review 4.  Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma.

Authors:  Michele Merli; Giuseppe Carli; Luca Arcaini; Carlo Visco
Journal:  World J Gastroenterol       Date:  2016-10-14       Impact factor: 5.742
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.